Is IQVIA Holdings Inc. (IQV) a Buy, Sell, or Hold?
IQVIA Holdings Inc.
NYSE:IQV
$207.83 USD
$0.28 (0.13%)
- Volume
- 1.1M
- Average Volume
- 1.66M
- Market Capitalization
- $34.69B
- P/E Ratio
- 25.53
- Dividend Yield
- 0.00%
- Price Target
- $240.00
- Year High
- $247.05
- Year Low
- $154.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.75
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Ari Bousbib |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | IQV |
| CUSIP | 46266C105 |
| CIK | 0001478242 |
| Web | https://www.iqvia.com |
| Phone | 919 998 2000 |
| Currency | USD |
| Employees | 93000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.58 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.75 |
| Quick Ratio | 0.75 |
| Cash Ratio | 0.23 |
Sales & Book Value
| Annual Sales | $16.31B |
| Price / Sales | 2.09 |
| Cash Flow | 15.11 |
| Price / Cash Flow | 13.63 |
| Price / Book | 5.63 |
Price Target and Rating
| Average Stock Price Forecast | $240.00 |
| High Stock Price Forecast | $250.00 |
| Low Stock Price Forecast | $185.00 |
| Forecast Upside/Downside | -13.40% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 44 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $7.84 |
| Trailing P/E Ratio | 25.53 |
| PEG Ratio | 2.63 |
| P/E Growth | 2.63 |
| Net Income | $1.36B |
| Net Margin | 8.33% |
| Pretax Margin | 9.81% |
| Return on Equity | 22.46% |
| Return on Assets | 4.67% |
Financials Score
| AltmanZ Score | 1.99 |
| Piotroski Score | 5.00 |
| Working Capital | -2.11B |
| Total Assets | 29.68B |
| Ebit | 2.35B |
| Market Cap | 34.64B |
| Total Liabilities | 23.33B |
Poll Results
About IQVIA Holdings Inc. (NYSE:IQV) Stock
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers str ... ategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV vs. PEN: Which Stock Is the Better Value Option?
2026-07-14 12:40:26
Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
2026-07-09 10:41:34
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Hold IQV Stock in Their Portfolios Now
2026-07-03 09:55:46
IQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.
StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising
2026-06-18 10:17:00
TORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compliant engagement with healthcare audiences. IQVIA Digital's integrated solutions enable marketers to quickly transform data-driven insights into meaningful, privacy-conscious activation across the healthcare ecosystem.Through this collaboration, StackAdapt's programmatic advertising capabilities are n.
2026-06-17 12:30:08
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term
2026-06-17 10:40:16
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2026-06-17 08:00:44
Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity
2026-06-15 12:17:31
IQVIA Holdings gains from its vast healthcare data, AI-driven analytics & global IT infrastructure, supporting expansion and solid growth.
Frequently Asked Questions
-
What is the current IQVIA Holdings Inc. (IQV) stock price?
-
IQVIA Holdings Inc.(NYSE:IQV) stock price is $207.83 in the last trading session. During the trading session, IQV stock reached the peak price of $247.05 while $154.5 was the lowest point it dropped to. The percentage change in IQV stock occurred in the recent session was 0.13% while the dollar amount for the price change in IQV stock was $0.28.
-
IQV's industry and sector of operation?
-
The NYSE listed IQV is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of IQV?
-
Duane Sachs | Senior Vice President of Corporate Development
Ari Bousbib | Chief Executive Officer & Chairman
Eric Sherbet | Executive Vice President, General Counsel & Secretary
Jeffrey A. Spaeder | Chief Medical & Scientific Officer
Kerri Joseph | Senior VP of Investor Relations & Treasurer -
How many employees does IQV have?
-
Number of IQV employees currently stands at 93000. IQV operates from 2400 Ellis Road, Durham, NC 27703, US.
-
Link for IQV official website?
-
Official Website of IQV is: https://www.iqvia.com
-
How do I contact IQV?
-
IQV could be contacted at phone #919 998 2000 and can also be accessed through its website. IQV operates from 2400 Ellis Road, Durham, NC 27703, US.
-
How many shares of IQV are traded daily?
-
The average number of IQV shares traded daily for last 3 months was 1.66M.
-
What is the market cap of IQV currently?
-
The market value of IQV currently stands at $34.69B with its latest stock price at $207.83